HedgePath Pharmaceuticals
OTC: INTITampa, US · Delaware corporation
Founders & leadership
FE
Frank E. O'Donnell, Jr., MDExecutive
NJ
Nicholas J. VircaExecutive
GH
Garrison Hasara, CPAExecutive
Board
SJ
Stefan J. CrossBoard director
SP
Samuel P. Sears, Jr.Board director
RD
R. Dana Ono, MDBoard director
WM
W. Mark Watson, CPABoard director
Reported raises · per SEC filings
Form D private placements$600K disclosed across 1 round · 2016
▶$600KraisedApr 2016 · 3 investors · PharmaceuticalsRule 506(c)
▶$600KraisedApr 2016 · 3 investors · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- Samuel P. Sears, Jr.Director
- R. Dana Ono, MDDirector
- Frank E. O'Donnell, Jr., MDExecutive Officer, Director
- Nicholas J. VircaExecutive Officer
- W. Mark Watson, CPADirector
- Garrison Hasara, CPAExecutive Officer
- Stefan J. CrossDirector
- Offering amount
- $5.5M
- Amount sold
- $600K
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- How much funding has HedgePath Pharmaceuticals raised?
- HedgePath Pharmaceuticals has disclosed $600K raised across 1 round.
- Where is HedgePath Pharmaceuticals headquartered?
- HedgePath Pharmaceuticals is headquartered in Tampa, US.